Concepedia

RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer

Yajing Liu, Monika L. Burness, Rachel Martin-Trevino, Joey Guy, Shoumin Bai, Ramdane Harouaka, Michael Brooks, Shang Li, Tahra Luther, April Davis,

Clinical Cancer Research · 2016 · 152 citations · 33 references

DOI

Abstract

Our data suggest that in both BRCA1-mutant and BRCA1-wild-type TNBCs, CSCs are relatively resistant to PARP inhibition. This resistance is mediated by RAD51, suggesting that strategies aimed at targeting RAD51 may increase the therapeutic efficacy of PARPi. Clin Cancer Res; 23(2); 514-22. ©2016 AACR.

References

33

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.5K citations

, , +7

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · Nature · 2005 · 5.1K citations

, , +7

ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome

Christophe Ginestier, Min Hee Hur, Emmanuelle Charafe‐Jauffret et al. · Cell stem cell · 2007 · 4K citations · Full text

, , +9

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

, , +7